Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B/myeloid acute bilineal leukemia.

Shoji Saito,Chiaki Taira,Kazuyuki Matsuda,Ryu Yanagisawa,Daisuke Morita,Tomonari Shigemura,Kentaro Yoshikawa,Miyuki Tanaka,Kazuo Sakashita,Saki Mukai,Shigetaka Shimodaira,Kenichi Koike,Yozo Nakazawa

Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B/myeloid acute bilineal leukemia.

2019

Shoji Saito
Chiaki Taira
Kazuyuki Matsuda
Ryu Yanagisawa
Daisuke Morita
Tomonari Shigemura
Kentaro Yoshikawa
Miyuki Tanaka
Kazuo Sakashita
Saki Mukai
Shigetaka Shimodaira
Kenichi Koike
Yozo Nakazawa

Historically defined in the European Group for the Immunological Characterization of Leukemias (EGIL) [1], acute bilineal leukemia (ABLL) is characterized by 2 distinct blast populations (e.g. B/my...

Keywords:

Disease Response
Medicine
Acute bilineal leukemia
Myeloid
Oncology
Diabetes mellitus
Immunology
Internal medicine
Chemotherapy
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations